Losartan blocks osteosarcoma-elicited monocyte recruitment, and combined with the kinase inhibitor toceranib, exerts significant clinical benefit in canine metastatic …

DP Regan, L Chow, S Das, L Haines, E Palmer… - Clinical Cancer …, 2022 - AACR
Purpose: There is increasing recognition that progress in immuno-oncology could be
accelerated by evaluating immune-based therapies in dogs with spontaneous cancers …
被引用次数：46 相关文章

Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine …

DP Regan, L Chow, S Das, L Haines… - … : an official journal …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose There is increasing recognition that progress in immuno-oncology could be
accelerated by evaluating immune-based therapies in dogs with spontaneous cancers …

Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine …

DP Regan, L Chow, S Das, L Haines… - … Cancer Research: an …, 2022 - europepmc.org
Purpose There is increasing recognition that progress in immuno-oncology could be
accelerated by evaluating immune-based therapies in dogs with spontaneous cancers …
[HTML] nih.gov

[HTML][HTML] Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in …

DP Regan, L Chow, S Das, L Haines… - Clinical Cancer …, 2022 - ncbi.nlm.nih.gov
Purpose: There is increasing recognition that progress in immuno-oncology could be
accelerated by evaluating immune-based therapies in dogs with spontaneous cancers …
[HTML] nih.gov

[HTML][HTML] Losartan blocks osteosarcoma-elicited monocyte recruitment, and combined with the kinase inhibitor toceranib, exerts significant clinical benefit in canine …

DP Regan, L Chow, S Das, L Haines… - … cancer research: an …, 2022 - ncbi.nlm.nih.gov
Purpose: There is increasing recognition that progress in immuno-oncology could be
accelerated by evaluating immune-based therapies in dogs with spontaneous cancers …